Phase III
On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
Avadel Pharmaceuticals plc announced that it has achieved its patient enrollment target of 205 patients in the REST-ON Phase 3 clinical trial for its once-nightly sodium oxybate, FT218.
Allergy Therapeutics plc provides an update on its Grass MATA MPL phase III study, due to start in Autumn 2020.
Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks
The trial studied the efficacy and safety of adjunctive pimavanserin dosages in patients with predominantly negative symptoms of schizophrenia who had adequate control of positive symptoms with their current antipsychotic treatment.
The company’s shares exploded 300% in after-hours trading yesterday at the news, giving the company a market value of $469.6 million.
Tecentriq is the company’s PD-L1 checkpoint inhibitor. Avastin is an antibody that binds to VEGF and interferes with tumor blood supply.
The drug combination did not hit the co-primary endpoint of recurrence-free survival in patients whose tumors expressed PD-L1 greater than 1%.
Amidst rumors that Novartis might be interested in an acquisition, The Medicines Company announced data from ORION-10, the second of three 19-month Phase III trials of inclisiran for lowering cholesterol.
PRESS RELEASES